**Abstract**

Numerous studies measuring pro-inflammatory cytokines in blood demonstrate that a subpopulation of psychiatric patients exhibit inflammation. In post-mortem and imaging studies, neuroinflammation was indicated by the presence of activated microglia ^\[1,2\].^ Since tryptophan catabolism increases in activated microglia, tryptophan catabolites (TRYCATs) are possibly novel biomarkers of neuroinflammation-induced psychiatric symptoms.

**Specific objectives:** A) Assess TRYCATs in animal models of neuroinflammation to determine utility as an endpoint for therapeutic intervention. B) Assess TRYCAT levels from psychiatric patients and controls as a potential clinical biomarker for patient stratification.

**Methods Used:** LPS model: LPS was injected i.c.v. to mice, and brains were collected 24 hours later. Chronic Social Defeat model: Mice were subjected to chronic social defeat in a standard paradigm. Brains were collected on the final day of testing. Clinical samples were obtained from the Universitätsklinikum Ulm, Germany. TRYCATs in mouse brain tissue homogenates/plasma and human CSF/plasma were analysed using liquid chromatography-tandem mass spectrometry.

**Results:** LPS model: A robust increase in all TRYCATS from brain homogenates was observed in all LPS treated animals. Chronic social defeat model: No change in TRYCATs was observed in mice subjected to chronic stress. However, a significant proportion of microglia became activated following chronic social defeat. Inhibition of the IDO1 enzyme, which catalyses the first step in the TRYCAT pathway, reversed TRYCAT induction in the LPS model, as well as behavioral alterations in chronic social defeat. Results from the clinical samples indicate that patients exhibit an altered TRYCAT profile, and that CSF and plasma TRYCATs appear to be independently regulated.

**Conclusion:** TRYCAT levels provide a useful tool for preclinical models of neuroinflammation and treatment. A first study of TRYCATs in a patient population suggests potential use as a clinical biomarker.
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